<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3355">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282135</url>
  </required_header>
  <id_info>
    <org_study_id>IMS 1</org_study_id>
    <nct_id>NCT04282135</nct_id>
  </id_info>
  <brief_title>Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling</brief_title>
  <official_title>Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Bayreuth GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Bayreuth GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as
      screening tool for the detection of Influenza and SARS-CoV-2- infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial infections can be distinguished by analysis of the volatile organic compounds found
      in breath.

      In patients with suspected Influenza infection, nasal air samples will be taken and analyzed
      by Multicapillary Ion mobility spectrometry (MCC IMS). Routinely all patients undergo
      polymerase chain reaction (PCR) analysis of nasopharyngeal swabs for Influenza.

      MCC IMS spectra will be compared between infected and non infected patients by cluster
      analysis and discrimination analysis.

      If the number of infected patients exceeds 50 an additional validation cohort will be
      investigated sequentially otherwise validation will be performed during the Influenza
      epidemic 2021.

      Due to decreasing numbers of Influenza-A- Infections study was opened to also include
      patients with suspected SARS-CoV-2 infections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cluster Analysis of MCC IMS spectra.</measure>
    <time_frame>immediatly after sampling</time_frame>
    <description>Cluster Analysis of MCC IMS spectra will be obtained immediately after sampling</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">76</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Infected</arm_group_label>
    <description>patients with detected Influenza RNA in nasopharyngeal swabs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>not infected</arm_group_label>
    <description>patients without detected Influenza RNA in nasopharyngeal swabs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS CoV2</arm_group_label>
    <description>patients with SARS-Cov-2 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MCC IMS</intervention_name>
    <description>Diagnosis by MCC IMS</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>SARS CoV2</arm_group_label>
    <arm_group_label>not infected</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        general population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspected Influenza infection

        Exclusion Criteria:

          -  later than 48h after admission and detection of Influenza infection

          -  later than 32 days after admission and detection of SARS-CoV-2- infection

          -  no written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Steppert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Bayreuth, Dpt. Pulmonology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Bayreuth GmbH</investigator_affiliation>
    <investigator_full_name>Claus Steppert</investigator_full_name>
    <investigator_title>Director Department of pulmonology and thoracic oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

